Terminated PHASE3 INTERVENTIONAL 2-arm NCT05002569

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma (RELATIVITY-098)

A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab + Relatlimab Fixed-dose Combination Versus Nivolumab Monotherapy After Complete Resection of Stage III-IV Melanoma

Sponsor: Bristol-Myers Squibb

Conditions Melanoma

Interventions Nivolumab Nivolumab + Relatlimab Fixed Dose Combination

Updated 22 times since 2021 Last updated: Dec 29, 2025 Started: Oct 19, 2021 Primary completion: Dec 16, 2024 Completion: Apr 2, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Inability to meet protocol objectives

Other terminated trials from Bristol-Myers Squibb

See all terminations from Bristol-Myers Squibb

Other Melanoma trials with similar outcome

Browse all Melanoma trials

This PHASE3 trial investigates Melanoma and is currently terminated or withdrawn. Bristol-Myers Squibb leads this study, which shows 22 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

22 versions recorded

Feb 2026 — Present [monthly]

Terminated PHASE3
Sep 2025 — Feb 2026 [monthly]

Terminated PHASE3
Jun 2025 — Sep 2025 [monthly]

Terminated PHASE3

Status: Active Not Recruiting → Terminated
Feb 2025 — Jun 2025 [monthly]

Active Not Recruiting PHASE3
Sep 2024 — Feb 2025 [monthly]

Active Not Recruiting PHASE3

▶ Show 17 earlier versions

Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE3
Oct 2023 — Jul 2024 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Aug 2023 — Oct 2023 [monthly]

Recruiting PHASE3
Jul 2023 — Aug 2023 [monthly]

Recruiting PHASE3
Jun 2023 — Jul 2023 [monthly]

Recruiting PHASE3
May 2023 — Jun 2023 [monthly]

Recruiting PHASE3
Apr 2023 — May 2023 [monthly]

Recruiting PHASE3
Jan 2023 — Apr 2023 [monthly]

Recruiting PHASE3
Dec 2022 — Jan 2023 [monthly]

Recruiting PHASE3
Nov 2022 — Dec 2022 [monthly]

Recruiting PHASE3
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE3
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE3
Jun 2022 — Jul 2022 [monthly]

Recruiting PHASE3
May 2022 — Jun 2022 [monthly]

Recruiting PHASE3
Apr 2022 — May 2022 [monthly]

Recruiting PHASE3
Mar 2022 — Apr 2022 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Sep 2021 — Mar 2022 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb

Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalborg, Denmark , Aarhus, Denmark , Afula, Israel , Allentown, United States , Ann Arbor, United States , Athens, Greece , Atlanta, United States , Aurora, United States , Austin, United States , Badajoz, Spain and 157 more locations